Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Effect of Collavant® n2 in Healthy Male Adults With Exercise-induced Joint Discomfort. (COLLMOTION)

11 mai 2026 mis à jour par: Bioiberica

A Randomized, Double-blind, Placebo-controlled Clinical Study to Assess the Effect of Collavant® n2 on Joint Function and Performance in Healthy, Active Male Adults With Exercise-induced Joint Discomfort.

The present clinical study has been designed to evaluate the effect of Collavant® n2 at a daily dose of 40 mg on joint function and performance in healthy, amateur male runners with exercise-induced knee discomfort.

Aperçu de l'étude

Description détaillée

The COLLMOTION study is a randomized, double-blind, placebo-controlled, parallel clinical study designed to evaluate the effects of Collavant® n2 on joint function, performance and discomfort in healthy, physically active male adults experiencing exercise-induced knee discomfort.

A total of 80 healthy male amateur runners aged 40 to 65 years are enrolled and randomized in a 1:1 ratio to receive either Collavant® n2 (40 mg/day) or placebo for a total intervention period of 24 weeks. Eligible participants are required to train regularly (≥150 minutes per week), report persistent exercise-related knee discomfort, and meet predefined inclusion and exclusion criteria to ensure the absence of diagnosed knee pathology such as osteoarthritis.

The primary objective of the study is to assess differences from baseline and versus placebo in joint discomfort. Secondary objectives include the evaluation of joint function, physical performance, perceived exertion, pain intensity before exercise, time to pain recovery, and joint inflammation.

Safety and tolerability are evaluated throughout the study via monitoring of adverse events, vital signs, physical examinations, laboratory parameters, and quality-of-life assessments. Participants undergo assessments at baseline, 12 weeks, and 24 weeks.

Type d'étude

Interventionnel

Inscription (Estimé)

80

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Madrid
      • Madrid, Madrid, Espagne, 28040
        • Recrutement
        • Universidad Politécnica de Madrid
        • Contact:
        • Contact:
        • Chercheur principal:
          • Marcela González-Gross, Professor
        • Chercheur principal:
          • Javier Modrego-Martin, Doctor

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Healthy physically active male adults (amateur runners) with exercise-induced joint discomfort, aged between 40 and 65 years
  • Activity level: Amateur runners who train regularly a minimum of 150 minutes per week, divided into 2 or more sessions per week during at least 3 months. Principally, subjects training for popular running events of 10 Kms.
  • Joint discomfort after activity: Self-reports target knee discomfort after training by a score of at least 20 mm VAS at screening. Discomfort persistent for at least 2w.
  • Be willing to refrain from starting any new dietary supplements during the entire study that have any underlying joint benefits (collagen, glucosamine, chondroitin, MSM, Hyaluronic Acid, Turmeric, Natural Eggshell Membrane, Omega-3 fatty acids, PEA, Boswellia,..). If any of these supplements (except collagen) or any other dietary supplement has been taken consistently for at least 6 months prior to enrollment, participants should maintain the same stable intake pattern throughout the 24 week study period.
  • Have individual devices to monitor training with GPS
  • Sign informed consent

Exclusion Criteria:

  • Diagnostic of knee osteoarthritis or any pathology or surgical intervention associated with the knee.
  • Hypersensitivity to any component of the supplement or the placebo
  • Chronic treatment with analgesic or anti-inflammatory (NSAIDs and corticosteroids families) drugs
  • Treatment with any type of collagen supplement
  • Treatment with probiotics or antibiotics
  • Inability to train for the next 24 weeks
  • Follow a vegan diet

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Autre
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Quadruple

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Placebo
Placebo. 1 capsule / day
Expérimental: Collavant® n2
Native type II collagen (Collavant® n2)

Native type II collagen (Collavant® n2).

1 capsule 40 mg / day

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in Exercise-Induced Knee Joint Discomfort
Délai: Baseline (week 0) to week 24
Joint discomfort will be assessed using a Visual Analogue Scale (VAS) to quantify knee pain intensity associated with physical activity. The primary endpoint is the change in knee joint discomfort from baseline, comparing Collavant® n2 versus placebo. VAS scores will be collected under standardized conditions after the running test, to capture exercise-induced discomfort.
Baseline (week 0) to week 24

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in joint pain intensity after physical activity
Délai: Baseline (week 0) to week 12
Knee pain intensity following the running test will be measured using a Visual Analogue Scale (VAS).
Baseline (week 0) to week 12
Change in joint pain intensity before physical activity
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Knee pain intensity will be assessed using a Visual Analogue Scale (VAS) prior to performing the standardized running test.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Time to recovery of knee pain after exercise
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
The time required for knee pain to return to the participant's pre-exercise baseline level following the running test will be recorded by participant self-report.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Change in physical performance during the running test
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Physical performance will be assessed by recording completion time (in seconds) for a standardized running test.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Change in perceived exertion during physical activity
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Perceived exertion will be assessed using the Borg Rating of Perceived Exertion (RPE) scale immediately after the running test.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Change in knee joint function
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Knee function will be evaluated using the Knee Injury and Osteoarthritis Outcome Score (KOOS), a validated questionnaire assessing pain, symptoms, activities of daily living, sport/recreation function, and knee-related quality of life.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Change in knee joint inflammation
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Thermal response of the knee joint will be evaluated using infrared thermography before exercise, immediately after exercise, and 30 minutes post-exercise to assess exercise-induced inflammatory response.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Change in cartilage biomarkers
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Blood and urine biomarkers related to cartilage turnover and inflammation will be measured.
Baseline (week 0) to week 12, baseline (week 0) to week 24

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Change in clinical knee examination
Délai: Baseline (week 0) to week 12, baseline (week 0) to week 24
Clinical assessment of patellofemoral pain using the Zohlen test will be performed before and after the running test.
Baseline (week 0) to week 12, baseline (week 0) to week 24
Incidence of Adverse Events
Délai: Baseline (week 0) to week 24
Number and percentage of participants experiencing adverse events classified by severity and relationship to the study intervention.
Baseline (week 0) to week 24
Changes in Vital Signs
Délai: Baseline (week 0) to week 24
Change from baseline in vital signs: systolic and diastolic blood pressure (mmHg) and heart rate (beats per minute).
Baseline (week 0) to week 24
Changes in clinical laboratory parameters
Délai: Baseline (week 0) to week 24
Change from baseline in clinical laboratory parameters: hematology and blood biochemistry values.
Baseline (week 0) to week 24
Changes in physical activity level
Délai: Baseline (week 0) to week 24
Change from baseline in participant-reported physical activity level assessed using IPAQ questionnaire.
Baseline (week 0) to week 24
Change in dietary habits
Délai: Baseline (week 0) to week 24
Change from baseline in participant-reported dietary intake assessed using the Mediterranean Diet Adherence Questionnaire.
Baseline (week 0) to week 24
Change in Quality of Life score
Délai: Baseline (week 0) to week 24
Change from baseline in quality of life score assessed using the Quality of Life questionnaire SF-12
Baseline (week 0) to week 24
Change in muscle strength assessed by handgrip dinamometry
Délai: Baseline (week 0) to week 24]
Change from baseline in muscle strength (in Kg or Newtons) assessed by handgrip dynamometry.
Baseline (week 0) to week 24]

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Les enquêteurs

  • Chercheur principal: Marcela González-Gross, Professor, Universidad Politécnica de Madrid
  • Chercheur principal: Javier Modrego-Martin, Doctor, Universidad Politécnica de Madrid

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

6 mai 2026

Achèvement primaire (Estimé)

1 mars 2027

Achèvement de l'étude (Estimé)

1 mars 2027

Dates d'inscription aux études

Première soumission

10 avril 2026

Première soumission répondant aux critères de contrôle qualité

24 avril 2026

Première publication (Réel)

1 mai 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 mai 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 mai 2026

Dernière vérification

1 avril 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner